Kisqali Femara Co-Pack — Cigna
Breast Cancer – Early
Initial criteria
- Patient age ≥ 18 years
 - Patient has hormone receptor positive (HR+) [estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)] disease
 - Patient has HER2-negative breast cancer
 - Patient has early breast cancer (stage II or III) at high risk of recurrence (any lymph node involvement OR tumor size >5 cm OR tumor size 2–5 cm with either grade 2 and high genomic risk or Ki-67 ≥ 20% OR grade 3 disease)
 - Patient is a postmenopausal woman OR a pre/perimenopausal woman receiving ovarian suppression/ablation with a GnRH agonist OR has had surgical bilateral oophorectomy or ovarian irradiation OR is a man receiving a GnRH analog
 
Approval duration
3 years